San Antonio, Texas USA (UroToday.com) Scott Regenbogen, University of Michigan, discussed colon cancer surveillance in comparison to that used in urologic oncology.
Despite level one evidence in colorectal surgery there are limited risk stratification with infinite variations in surveillance modalities with evolving technology which makes guideline recommendations for surveillance recommendations challenging. Given the numerous risk factors associated with colorectal cancer and various imaging modalities it is increasingly difficult to provide ‘high level’ evidence to support the optimal surveillance strategy. Unfortunately, there have been reported no survival difference among those having more intense surveillance versus those that either have limited to no surveillance. In the OPRA trial assessing colorectal surveillance the results regarding surveillance were similar. Thus, while urologists may feel uncertain regarding surveillance strategies among urologic cancers we are not alone as illustrated by our colorectal colleagues.
Presented By: Scott Regenbogen, University of Michigan
Written By: Stephen B. Williams, MD and Ashish M. Kamat
17th Annual Meeting of the Society of Urologic Oncology - November 30 -December 2, 2016 – San Antonio, Texas USA